10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Saturday, October 10, 2009

Ranbaxy Laboratories Ltd:Future growth outlook and analysis

Scripscan:Ranbaxy Laboratories Ltd

Story:Ranbaxy earns 80% of its revenues from overseas . Japanese pharma major Daiichi Sankyo acuired it in June 2008. Soon after the acquisition, the company faced tough time with the US Food and Drug Administration (FDA) imposing regulatory clamps on manufacture of certain drugs at its two sites in India. It also suffered huge forex losses due to rupee depreciation. These setbacks led to a 70% fall in Ranbaxy''s stock from September last year to March this year.For now, early resolution of issues with US FDA is the priority for Ranbaxy. The Dewas facility is expected to receive FDA clearance in next 4-6 months. In the June quarter, its sales in Europe (except Romania), while still being lower than the year-ago levels, were more than the March quarter. The company has changed its strategy from being a volume-based player to one protecting its bottom line in Europe. Ranbaxy has now turned its attention to emerging markets which contribute around 57% of the company''s consolidated sales. In India, it has retained its second rank in the domestic formulations market. Ranbaxy is also growing in consumer healthcare space with products in nutrition and pain relieving segments. It has also commenced Phase-III clinical trials for its anti-malaria combination drug. The FDA action hit the company adversely in the US, its largest market, over the last four quarters. Consis-tent rupee depreciation in 2008 and large exposure to international markets resulted in forex losses of Rs 1,086 crore on foreign currency derivatives and loans. After suffering operational losses for two consecutive quarters, the company has managed to report operating profit for the latest quarter ended June 2009. While it is largely due to the forex gains arising on account of rupee appreciation, there are also signs of recovery in the company''s business. The company has received product approvals in Canada and US. It has also acquired brands in dermatology and pain management segment in India.The company has given its guidance of a net loss of about Rs 800 crore on sales of Rs 7,000 crore for year ending December 2009. At the current state of recovery, long-term investors are recommended to accumulate the company''s stock at the current lower levels rather than later when the recovery is complete.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner